Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody immunoconjugates - ImmunGene

Next Previous
Drug Profile

Research programme: monoclonal antibody immunoconjugates - ImmunGene

Alternative Names: IGN 004; IGN 005; IGN 006; mAb-IFN fusion proteins - ImmunGene; mAB-IFN therapeutics - ImmunGene; Monoclonal antibody fusion proteins - ImmunGene

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunGene
  • Class Chemokines; Cytokines; Immunoconjugates; Interferons; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Interferon replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Malignant melanoma; Solid tumours

Most Recent Events

  • 28 Aug 2023 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
  • 28 Aug 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 08 Jul 2019 Preclinical trials in Malignant melanoma in USA (Parenteral) before July 2019 (Spectrum Pharmaceuticals pipeline, July 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top